Scott Uretsky, MD
Neurology · New Hyde Park, NYNPI 1952598179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Amgen accounts for 67.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $3,147 and has fallen 99.2% since, to $24 in 2025.
Across 65 payments — averaging $86.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- ANI Pharmaceuticals, Inc.$768
- Mallinckrodt Hospital Products Inc.$642
- AstraZeneca$137
- AbbVie$108
- Alcon$57
- plus $100 from 3 others
What the payments were for
- Speaking & faculty fees$3,00053%
- Food & beverage$2,54345%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 30 | $3,830 |
| ANI Pharmaceuticals, Inc. | 2 | $768 |
| Mallinckrodt Hospital Products Inc. | 18 | $642 |
| AstraZeneca | 2 | $137 |
| AbbVie(2 entities) | 6 | $108 |
| Alcon | 3 | $57 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Biotissue Holdings Inc. | 1 | $37 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$3,000
- PURIFIED CORTROPHIN GEL$743
- UPLIZNA$104
How this compares
$5,643 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 21 | $2,831 |
| Acetazolamide | 33 | $1,938 |
| Pyridostigmine Bromide | 20 | $1,794 |
| Pregabalin | 18 | $878 |
| Acetazolamide ErAcetazolamide | 11 | $741 |
| Gabapentin | 12 | $543 |
| Memantine Hcl | 23 | $441 |
| Baclofen | 17 | $372 |
| Latanoprost | 37 | $321 |
| Prednisone | 24 | $154 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Hyde Park
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.